Unknown

Dataset Information

0

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.


ABSTRACT:

Background

The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we determined whether these goals are reflected in current clinical practice once FH has been diagnosed.

Methodology/principal findings

In 2008, we sent questionnaires to all subjects (aged 18-65 years) who were molecularly diagnosed with FH in the year 2006 through the screening program in The Netherlands. Of these 1062 subjects, 781 completed the questionnaire (46% males; mean age: 42+/-12 years; mean LDL-C at molecular diagnosis (baseline): 4.1+/-1.3 mmol/L). The number of persons that used cholesterol-lowering therapy increased from 397 (51%) at baseline to 636 (81%) after diagnosis. Mean treated LDL-C levels decreased significantly to 3.2+/-1.1 mmol/L two years after diagnosis. Only 22% achieved the LDL-C target level of < or = 2.5 mmol/L.

Conclusions/significance

The proportion of patients using cholesterol-lowering medication was significantly increased after FH diagnosis through genetic cascade screening. The attained LDL-C levels were lower than those reported in previous surveys on medication use in FH, which could reflect the effect of more stringent lipid target levels. However, only a minority of the medication users reached the LDL-C target.

SUBMITTER: Huijgen R 

PROVIDER: S-EPMC2821409 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

Huijgen Roeland R   Kindt Iris I   Verhoeven Sjoerd B J SB   Sijbrands Eric J G EJ   Vissers Maud N MN   Kastelein John J P JJ   Hutten Barbara A BA  

PloS one 20100215 2


<h4>Background</h4>The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we determined whether these goals are reflected in current clinical practice once FH has been diagnosed.<h4>Methodology/principal findings</h4>In 2008, we sent questionnaires to all subjects (aged 18-65  ...[more]

Similar Datasets

| S-EPMC548411 | biostudies-literature
| S-EPMC8468752 | biostudies-literature
| S-EPMC9131112 | biostudies-literature
| S-EPMC5015370 | biostudies-literature
| S-EPMC3477057 | biostudies-literature
2008-04-01 | GSE6054 | GEO
| S-EPMC2633353 | biostudies-literature
| S-EPMC9863418 | biostudies-literature
| S-EPMC7653043 | biostudies-literature
| S-EPMC10707129 | biostudies-literature